Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 3Neoplasm Metastasis 2Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell 2Uterine Cervical Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Mesothelioma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoblastic Lymphadenopathy 1Gliosarcoma 1Glioma 1Glioblastoma 1Enteropathy-Associated T-Cell Lymphoma 1Brain Neoplasms 1

Interventions

Cyclophosphamide 4Vincristine 3Doxorubicin 3romidepsin 2fludarabine 2Rituximab 2Oxaliplatin 2Lenalidomide 2Etoposide 2Azacitidine 2Alemtuzumab 2siplizumab 1obatoclax 1liposomal doxorubicin 1gossypol acetic acid 1fludarabine phosphate 1cediranib 1cc-486 1Valproic Acid 1Taxes 1Sunitinib 1Spinal Puncture 1Sorafenib 1Receptors, Chimeric Antigen 1Razoxane 1Prednisone 1Prednisolone 1Polymerase Chain Reaction 1Paclitaxel 1Magnetic Resonance Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoma, T-Cell, Peripheral × Automobiles × Clear all
NCT03049449 2023-01-18

T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
26 enrolled 19 charts
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡